389 related articles for article (PubMed ID: 21371604)
1. Experiences in fragment-based lead discovery.
Hubbard RE; Murray JB
Methods Enzymol; 2011; 493():509-31. PubMed ID: 21371604
[TBL] [Abstract][Full Text] [Related]
2. Target immobilization as a strategy for NMR-based fragment screening: comparison of TINS, STD, and SPR for fragment hit identification.
Kobayashi M; Retra K; Figaroa F; Hollander JG; Ab E; Heetebrij RJ; Irth H; Siegal G
J Biomol Screen; 2010 Sep; 15(8):978-89. PubMed ID: 20817886
[TBL] [Abstract][Full Text] [Related]
3. Practical aspects of NMR-based fragment screening.
Lepre CA
Methods Enzymol; 2011; 493():219-39. PubMed ID: 21371593
[TBL] [Abstract][Full Text] [Related]
4. Combining biophysical screening and X-ray crystallography for fragment-based drug discovery.
Hennig M; Ruf A; Huber W
Top Curr Chem; 2012; 317():115-43. PubMed ID: 21837555
[TBL] [Abstract][Full Text] [Related]
5. From experimental design to validated hits a comprehensive walk-through of fragment lead identification using surface plasmon resonance.
Giannetti AM
Methods Enzymol; 2011; 493():169-218. PubMed ID: 21371592
[TBL] [Abstract][Full Text] [Related]
6. Effective progression of nuclear magnetic resonance-detected fragment hits.
Eaton HL; Wyss DF
Methods Enzymol; 2011; 493():447-68. PubMed ID: 21371601
[TBL] [Abstract][Full Text] [Related]
7. Advancing fragment binders to lead-like compounds using ligand and protein-based NMR spectroscopy.
Maurer T
Methods Enzymol; 2011; 493():469-85. PubMed ID: 21371602
[TBL] [Abstract][Full Text] [Related]
8. [Progress in the fragment-based drug discovery].
Ren J; Li J; Shi F; Wang X; He JH; Xu YC; Zhang NX; Xiong B; Shen JK
Yao Xue Xue Bao; 2013 Jan; 48(1):14-24. PubMed ID: 23600136
[TBL] [Abstract][Full Text] [Related]
9. Fragment-based drug discovery applied to Hsp90. Discovery of two lead series with high ligand efficiency.
Murray CW; Carr MG; Callaghan O; Chessari G; Congreve M; Cowan S; Coyle JE; Downham R; Figueroa E; Frederickson M; Graham B; McMenamin R; O'Brien MA; Patel S; Phillips TR; Williams G; Woodhead AJ; Woolford AJ
J Med Chem; 2010 Aug; 53(16):5942-55. PubMed ID: 20718493
[TBL] [Abstract][Full Text] [Related]
10. Fragment growing induces conformational changes in acetylcholine-binding protein: a structural and thermodynamic analysis.
Edink E; Rucktooa P; Retra K; Akdemir A; Nahar T; Zuiderveld O; van Elk R; Janssen E; van Nierop P; van Muijlwijk-Koezen J; Smit AB; Sixma TK; Leurs R; de Esch IJ
J Am Chem Soc; 2011 Apr; 133(14):5363-71. PubMed ID: 21322593
[TBL] [Abstract][Full Text] [Related]
11. Integrating surface plasmon resonance biosensor-based interaction kinetic analyses into the lead discovery and optimization process.
Danielson UH
Future Med Chem; 2009 Nov; 1(8):1399-414. PubMed ID: 21426056
[TBL] [Abstract][Full Text] [Related]
12. How well can fragments explore accessed chemical space? A case study from heat shock protein 90.
Roughley SD; Hubbard RE
J Med Chem; 2011 Jun; 54(12):3989-4005. PubMed ID: 21561141
[No Abstract] [Full Text] [Related]
13. Introduction to fragment-based drug discovery.
Erlanson DA
Top Curr Chem; 2012; 317():1-32. PubMed ID: 21695633
[TBL] [Abstract][Full Text] [Related]
14. Mass spectrometry for fragment screening.
Chan DS; Whitehouse AJ; Coyne AG; Abell C
Essays Biochem; 2017 Nov; 61(5):465-473. PubMed ID: 28986384
[TBL] [Abstract][Full Text] [Related]
15. A three-stage biophysical screening cascade for fragment-based drug discovery.
Mashalidis EH; Śledź P; Lang S; Abell C
Nat Protoc; 2013 Nov; 8(11):2309-24. PubMed ID: 24157549
[TBL] [Abstract][Full Text] [Related]
16. Experimental validation of a fragment library for lead discovery using SPR biosensor technology.
Elinder M; Geitmann M; Gossas T; Källblad P; Winquist J; Nordström H; Hämäläinen M; Danielson UH
J Biomol Screen; 2011 Jan; 16(1):15-25. PubMed ID: 21149860
[TBL] [Abstract][Full Text] [Related]
17. Native MS: an 'ESI' way to support structure- and fragment-based drug discovery.
Vivat Hannah V; Atmanene C; Zeyer D; Van Dorsselaer A; Sanglier-Cianférani S
Future Med Chem; 2010 Jan; 2(1):35-50. PubMed ID: 21426045
[TBL] [Abstract][Full Text] [Related]
18. Using computational techniques in fragment-based drug discovery.
Desjarlais RL
Methods Enzymol; 2011; 493():137-55. PubMed ID: 21371590
[TBL] [Abstract][Full Text] [Related]
19. A combinatorial biophysical approach; FTSA and SPR for identifying small molecule ligands and PAINs.
Redhead M; Satchell R; Morkūnaitė V; Swift D; Petrauskas V; Golding E; Onions S; Matulis D; Unitt J
Anal Biochem; 2015 Jun; 479():63-73. PubMed ID: 25837771
[TBL] [Abstract][Full Text] [Related]
20. Discovery and design of novel HSP90 inhibitors using multiple fragment-based design strategies.
Huth JR; Park C; Petros AM; Kunzer AR; Wendt MD; Wang X; Lynch CL; Mack JC; Swift KM; Judge RA; Chen J; Richardson PL; Jin S; Tahir SK; Matayoshi ED; Dorwin SA; Ladror US; Severin JM; Walter KA; Bartley DM; Fesik SW; Elmore SW; Hajduk PJ
Chem Biol Drug Des; 2007 Jul; 70(1):1-12. PubMed ID: 17630989
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
